Sandoz Group (VTX:SDZ) First Half 2024 Results
Key Financial Results
- Revenue: US$5.06b (up 2.7% from 1H 2023).
- Net income: US$150.0m (down 36% from 1H 2023).
- Profit margin: 3.0% (down from 4.8% in 1H 2023).
- EPS: US$0.35 (down from US$0.55 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sandoz Group EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 33%.
Looking ahead, revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Switzerland.
Performance of the Swiss Pharmaceuticals industry.
The company's shares are down 3.2% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Sandoz Group that you should be aware of before investing here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:SDZ
Sandoz Group
Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
Undervalued with reasonable growth potential.
